Negative allosteric modulators of MGLUR5 for use in the treatment of mature brain damages
Abstract:
The present disclosure relates to the use of negative allosteric modulators (NAMs) of the metabotropic glutamate receptor 5 (mGluR5) in the treatment of a mature brain damage, such as damage after stroke.
Information query
Patent Agency Ranking
0/0